Windward Bio plans $175M Nasdaq IPO

Swiss biotech Windward Bio set terms for a Nasdaq IPO, offering about 10.3 million shares at $16 to $18 each and seeking roughly $175 million, alongside a $50 million private placement from Sanofi. The company plans to use the funding chiefly to advance WIN378, a long-acting antibody targeting TSLP that is being tested for severe asthma and COPD, and to progress its pipeline, including a second antibody candidate targeting TSLP and IL-13. Windward says WIN378 could be dosed less frequently than existing treatments, and it has begun the Phase 3 portion of its asthma program. Its listing, planned under the ticker WWB, remains subject to Nasdaq approval.